Evaluation of Reference variability [Design Issues]

posted by Nirali – India, 2009-04-13 13:53 (6283 d 00:52 ago) – Posting: # 3515
Views: 6,604

Dear All,

We want to conduct BE replicate study to demonstrate that the within-subject variability for Cmax of the reference compound in the study is >30% for EU regulatory.

To check reference variablity which study design and model shall be used for statistical analysis?

Shall we use 2-period replicate design to assess the inter and intra-subject variability of reference drug, in which reference drug given in both the periods?

Thanks & Regards,
NIRALI

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
356 visitors (0 registered, 356 guests [including 26 identified bots]).
Forum time: 14:46 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5